Nurix Therapeutics Q1 2024 Earnings Report

Nurix Therapeutics EPS Results

• Actual EPS: -$0.76
• Consensus EPS: -$0.80
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: N/A

Nurix Therapeutics Revenue Results

• Actual Revenue: $16.59 million
• Expected Revenue: $14.58 million
• Beat/Miss: Beat by +$2.01 million
• YoY Revenue Growth: N/A

Nurix Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 4/10/2024
• Time: N/A

Nurix Therapeutics (NASDAQ:NRIX), a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.